The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Open accessAbstract
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, BRAF inhibitors led to a monotherapy response rate of >50% in BRAFV600E melanoma and ~30% in BRAFV600E NSCLC, but only ~5% in BRAFV600E colorectal cancer, likely due to the variable robustness of adaptive feedback networks in each tumor type (45–49).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,003
Zenda, S., Akimoto, T., Mizumoto, M., Hayashi, R., Arahira, S., Okumura, T., & Sakurai, H. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.10.025 · Cited by 48
Anforth, R. M., Blumetti, T. C. M. P., Clements, A., Kefford, R. F., Long, G. V., & Fernández‐Peñas, P. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12519 · Cited by 48
Self-citationGrippo, J. F., Zhang, W., Heinzmann, D., Yang, K., Wong, J., Joe, A. K., Münster, P. N., Sarapa, N., & DAUD, A. I. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2324-5 · Cited by 48
Self-citationLimited genomic heterogeneity of circulating melanoma cells in advanced stage patients
Velasco, C. R., Li, J., Luttgen, M. S., Kolatkar, A. R., Kendall, J., Flores, E. I., Topp, Z. Z., Samlowski, W. E., McClay, E. F., Bethel, K. J., et al. (2015) · Physical Biology · doi:10.1088/1478-3975/12/1/016008 · Cited by 48
Self-citationOptimal Management of Skin Cancer in Immunosuppressed Patients
Brin, L., Zubair, A. S., & Brewer, J. D. (2014) · American Journal of Clinical Dermatology · doi:10.1007/s40257-014-0085-5 · Cited by 49
Predictive biomarkers in precision medicine and drug development against lung cancer
Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0028-4 · Cited by 49
Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients
Nikanjam, M., Liu, S., Yang, J., & Kurzrock, R. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0357 · Cited by 48
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy
Han, C. H., & Brastianos, P. K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00230 · Cited by 48
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 50
Torres‐Collado, A. X., Knott, J., & Jazirehi, A. R. (2018) · Cancers · doi:10.3390/cancers10060157 · Cited by 48
Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma
Brummer, C., Färber, S., Bruß, C., Blank, C. U., Lacroix, R., Haferkamp, S., Herr, W., Kreutz, M. P., & Renner, K. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.018 · Cited by 48
Wang, S., Hwang, E. E., Guha, R., O'Neill, A. F., Melong, N., Veinotte, C. J., Saur, A. C., Wuerthele, K., Shen, M., McKnight, C. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0375 · Cited by 50
Metastatic melanoma – a review of current and future drugs
Velho, T. R. (2012) · Drugs in Context · doi:10.7573/dic.212242 · Cited by 50
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 47
Intra- and Inter-Tumoral Homogeneity of BRAFV600E Mutations in Melanoma Tumors
Riveiro‐Falkenbach, E., Villanueva, C. A., Garrido, M. C., Ruano, Y., García-Martín, R., Godoy, E., Ortiz-Romero, P. L., Ríos-Martín, J. J., Santos-Briz, A. J., & Rodríguez‐Peralto, J. L. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.229 · Cited by 47
Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice
Hinrichs, J. W. J., van Blokland, W. T. M., Moons, M. J., Radersma, R. D., Loon, J. H. R., de Voijs, C. M. A., Rappel, S. B., Koudijs, M. J., Besselink, N. J. M., Willems, S. M., et al. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp40xetvyamjpy · Cited by 47
The war on cancer: are we winning?
Duffy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0759-2 · Cited by 47
Co-development of a companion diagnostic for targeted cancer therapy
Cheng, S., Koch, W. H., & Wu, L. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.02.002 · Cited by 48
Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
Goldinger, S. M., Murer, C., Stieger, P., & Dummer, R. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.011 · Cited by 47
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Caputo, E., Miceli, R., Motti, M. L., Tatè, R., Fratangelo, F., Botti, G., Mozzillo, N., Carriero, M. V., Cavalcanti, E., Palmieri, G., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0216-z · Cited by 47
Dai, J., Kong, Y., Si, L., Chi, Z., Cui, C., Sheng, X., Mao, L., Li, S., Lian, B., Yang, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1266 · Cited by 47
Girotti, M. R., Saturno, G., Lorigan, P. C., & Marais, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.027 · Cited by 49
Loskog, A., Maleka, A., Mangsbo, S. M., Svensson, E., Lundberg, C. E., Nilsson, A., Krause, J., Agnarsdóttir, M., Sundin, A., Ahlström, H. K., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.42 · Cited by 47
Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool
Carter, J. H., Tseng, L., Zheng, G., Dudley, J. C., Illei, P. B., Gocke, C. D., Eshleman, J. R., & Lin, M. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp85atmjozoudj · Cited by 47
de Castro, D. G., Fearfield, L. A., Nathan, P., Tanière, P., Wallace, A. J., Brown, E. R., Harwood, C. A., Marsden, J. R., & Whittaker, S. J. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12248 · Cited by 47
PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation
Rodić, N., Anders, R. A., Eshleman, J. R., Lin, M.-T., Xu, H., Kim, J. H., Beierl, K., Chen, S., Luber, B. S., Wang, H., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0145 · Cited by 46
Achievements and Challenges of Molecular Targeted Therapy in Melanoma
Sullivan, R. J., LoRusso, P. M., Boerner, S. A., & Dummer, R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.177 · Cited by 49
Niu, H., Zhou, Q., Wang, F., Shao, Q., Guan, Y., Wen, X., Chen, L., Feng, Q., Li, W., Zeng, Y., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12129 · Cited by 46
Ott, P. A., Chang, J., Madden, K. M., Kannan, R., Muren, C., Escano, C., Cheng, X., Shao, Y., Mendoza, S., Gandhi, A., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1995-7 · Cited by 46
Self-citationAnforth, R. M., Menzies, A. M., Byth, K., Carlos, G., Chou, S., Sharma, R. N., Scolyer, R. A., Kefford, R. F., Long, G. V., & Fernández‐Peñas, P. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.01.018 · Cited by 46
Self-citationWilson, M. A., Zhao, F., Letrero, R., D'Andrea, K. P., Rimm, D. L., Kirkwood, J. M., Kluger, H. M., Lee, S. J., Schuchter, L. M., Flaherty, K. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0093 · Cited by 46
Self-citationKoetz‐Ploch, L., Hanniford, D., Dolgalev, I., Sokolova, E., Zhong, J., Díaz‐Martínez, M., Bernstein, E., Darvishian, F., Flaherty, K. T., Chapman, P. B., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12578 · Cited by 48
Self-citationConcurrent BRAF/MEK Inhibitors in BRAF V600–Mutant High-Grade Primary Brain Tumors
Schreck, K. C., Guajardo, A., Lin, D. D. M., Eberhart, C. G., & Grossman, S. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7052 · Cited by 46
E2F1 inhibition mediates cell death of metastatic melanoma
Rouaud, F., Hamouda‐Tekaya, N., Cerezo, M., Abbe, P., Zangari, J., Hofman, V., Ohanna, M., Mograbi, B., Hachem, N. E., Benfodda, Z., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0566-1 · Cited by 46
BRAF inhibitors: the current and the future
Zhang, W. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.015 · Cited by 48
Jansen, Y. J. L., Janssens, P., Hoorens, A., Schreuer, M. S., Seremet, T., Wilgenhof, S., & Neyns, B. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000186 · Cited by 46
Personalized Medicine in Oncology: Where Have we Come From and Where are we Going?
André, F., Ciccolini, J., Spano, J., Penault-Llorca, F. M., Mounier, N., Freyer, G., Blay, J., & Milano, G. A. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.79 · Cited by 45
Zebrafish as a model to assess cancer heterogeneity, progression and relapse
Blackburn, J. S., & Langenau, D. M. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.015842 · Cited by 52
Sundarasetty, B. S., Chan, L., Darling, D., Giunti, G., Farzaneh, F., Schenck, F., Naundorf, S., Kuehlcke, K., Ruggiero, E., Schmidt, M., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.43 · Cited by 45
Emerging targeted therapies for melanoma treatment (Review)
RUSSO, A., Ficili, B., Candido, S., Pezzino, F. M., Guarneri, C., Biondi, A., Travali, S., McCubrey, J. A., Spandidos, D. A., & Libra, M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2481 · Cited by 47
Genomic and Epigenomic Landscape in Meningioma
Bi, W. L., Mei, Y., Agarwalla, P. K., Beroukhim, R., & Dunn, I. F. (2016) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2015.11.009 · Cited by 45
Future Perspective of Single-Molecule FRET Biosensors and Intravital FRET Microscopy
Hirata, E., & Kiyokawa, E. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.01.037 · Cited by 45
Recent advances in the biology of human circulating tumour cells and metastasis
Gkountela, S., Szczerba, B. M., Donato, C., & Aceto, N. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000078 · Cited by 46
Liu, M., Yang, X., Liu, J., Zhao, B., Cai, W., Li, Y., & Hu, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15632 · Cited by 50
Countering TRAIL Resistance in Melanoma
Eberle, J. (2019) · Cancers · doi:10.3390/cancers11050656 · Cited by 46
Liu, X., Feng, Y., Xu, J., Shi, Y. K., Yang, J., Zhang, R., Song, J., Bai, X., Wu, X. L., Bao, Y., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.020 · Cited by 45
Gauging the Long-Term Benefits of Ipilimumab in Melanoma
Ribas, A., & Flaherty, K. T. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5041 · Cited by 46
Self-citationMutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Mancini, M., & Yarden, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.018 · Cited by 45
Novel Approaches in Melanoma Prevention and Therapy
Grimaldi, A. M., Cassidy, P. B., Leachman, S. A., & Ascierto, P. A. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5_25 · Cited by 44
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics
Ribas, A., Zhang, W., Chang, I., Shirai, K., Ernstoff, M. S., DAUD, A. I., Cowey, C. L., Daniels, G. A., Seja, E., O'Laco, E., et al. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.255 · Cited by 45
Self-citationLaurenzana, A., Margheri, F., Biagioni, A., Chillà, A., Pimpinelli, N., Ruzzolini, J., Peppicelli, S., Andreucci, E., Calorini, L., Serratì, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.024 · Cited by 45
The c-Jun/RHOB/AKT pathway confers resistance ofBRAF-mutant melanoma cells to MAPK inhibitors
Delmas, A., Cherier, J., Pohorecka, M., Giamarchi, C. M., Meyer, N., Casanova, A., Sordet, O., Lamant, L., Savina, A., Pradines, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3888 · Cited by 48
Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
Curl, P. K., Vujic, I., Veer, L. V. ‘., Ortiz‐Urda, S., & Kahn, J. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107255 · Cited by 44
Gross, A., Niemetz-Rahn, A., Nonnenmacher, A., Tucholski, J., Keilholz, U., & Fusi, A. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0318-9 · Cited by 43
Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
Wu, X., Marmarelis, M. E., & Hodi, F. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056134 · Cited by 43
Lih, C., Sims, D. J., Harrington, R. D., Polley, E. C., Zhao, Y., Mehaffey, M. G., Forbes, T. D., Das, B., Walsh, W. D., Datta, V., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.07.006 · Cited by 43
Ngiow, S. F., Meeth, K. M., Stannard, K. A., Barkauskas, D. S., Bollag, G. E., Bosenberg, M., & Smyth, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1089381 · Cited by 43
BRAF Inhibition inBRAFV600E-Positive Anaplastic Thyroid Carcinoma
Lim, A. M. L., Taylor, G. R., FELLOWES, A. P., Cameron, L., Lee, B., Hicks, R. J., McArthur, G. A., Angel, C. M., Solomon, B., & Rischin, D. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0030 · Cited by 43
Self-citationPrado, G., Svoboda, R. M., & Rigel, D. S. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2018.12.005 · Cited by 44
Current Treatment of Melanoma Brain Metastasis
Rishi, A., & Yu, H.-H. M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00733-z · Cited by 44
Targeting KRAS G12C with Covalent Inhibitors
Ostrem, J. M. L., & Shokat, K. M. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041621-012549 · Cited by 43
Autophagy in cancer immunotherapy: Perspective on immune evasion and cell death interactions
Yu, Q., Ding, J., Li, S., & Li, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216856 · Cited by 45
Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations
Berrocal, A., Cabañas, L., Espinosa, E., Fernández‐de‐Misa, R., Martín‐Algarra, S., Cedrés, J. C. M., Ríos‐Buceta, L., & Rodríguez‐Peralto, J. L. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0148-2 · Cited by 42
Important Role of Translational Science in Rare Disease Innovation, Discovery, and Drug Development
Pariser, A., & Gahl, W. A. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-2881-2 · Cited by 43
Bradish, J. R., Richey, J. D., Post, K. M., Meehan, K. L., Sen, J. D., Malek, A. J., Katona, T. M., Warren, S. J. P., Logan, T. F., Fecher, L. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.136 · Cited by 42
Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib
Doudican, N. A., & Orlow, S. J. (2016) · Oncogene · doi:10.1038/onc.2016.214 · Cited by 45
Maleka, A., Åström, G., Byström, P., & Ullenhag, G. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2657-7 · Cited by 42
Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF V600E Conformation
Grasso, M. J., Estrada, M. A., Christian, V., Samanta, M., Maksimoska, J., Villanueva, J., Winkler, J. D., & Marmorstein, R. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00529 · Cited by 43
Kawakami, H., Huang, S., Pal, K., Dutta, S. K., Mukhopadhyay, D., & Sinicrope, F. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0017 · Cited by 43
Current biologics for treatment of biliary tract cancers
Zhao, D. Y., & Lim, K. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.05.04 · Cited by 42
Yang, J., Xu, J., Cheuy, L. Y., Gonzalez, R. C., Fisher, D. R., & Miao, Y. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00025 · Cited by 42
Self-citationTreating advanced melanoma: current insights and opportunities
Tronnier, M., & Mitteldorf, C. (2014) · Cancer Management and Research · doi:10.2147/cmar.s49494 · Cited by 41
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
Viganò, M., Milia, M. L., Grassini, M. V., Pugliese, N., Giorgio, M. D., & FAGIUOLI, S. (2023) · Cancers · doi:10.3390/cancers15061766 · Cited by 43
Escuin-Ordinas, H., Atefi, M. S., Fu, Y., Cass, A. A., Ng, C., Huang, R., Yashar, S., Comin-Anduix, B., Avramis, E. V., Cochran, A. J., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.005 · Cited by 42
Self-citationP-Selectin-Mediated Platelet Adhesion Promotes the Metastasis of Murine Melanoma Cells
Qi, C., Wei, B., Ye, J., Yang, Y., Li, B., Zhang, Q., Li, J., He, X., Lan, T., & Wang, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091320 · Cited by 41
Self-citationImpact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
Ott, P. A., & Bhardwaj, N. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00346 · Cited by 44
Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract
Tseng, D., Kim, J. J., Warrick, A., Nelson, D., Pukay, M., Beadling, C., Heinrich, M. C., Selim, M. A., Corless, C. L., & Nelson, K. C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.033 · Cited by 41
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
Henick, B. S., Herbst, R. S., & Goldberg, S. B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.955794 · Cited by 41
Zheng, G., Lin, M., Lokhandwala, P. M., Beierl, K. F., Netto, G. J., Gocke, C. D., Eshleman, J. R., McCarthy, E. F., & Illei, P. B. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21743 · Cited by 41
Wu, J. H., Cohen, D. N., Rady, P. L., & Tyring, S. K. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15348 · Cited by 41
Gorantla, V. C., & Kirkwood, J. M. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.010 · Cited by 44
Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process
Melixetian, M. B., Pelicci, P. G., & Lanfrancone, L. (2022) · Cells · doi:10.3390/cells11030577 · Cited by 40
Sadow, P. M., Priolo, C., Nanni, S., Karreth, F. A., Duquette, M. A., Martinelli, R., Husain, A., Clohessy, J. G., Kutzner, H., Mentzel, T., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju182 · Cited by 40
Long, G. V., Wilmott, J. S., Haydu, L. E., Tembe, V., Sharma, R. N., Rizos, H., Thompson, J. F., Howle, J. R., Scolyer, R. A., & Kefford, R. F. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12098 · Cited by 40
Self-citationMolecular targeted therapies in metastatic melanoma
Comfere, N. I., Chakraborty, & Wieland, W. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s44800 · Cited by 41
Melanoma Treatments: Advances and Mechanisms
Marzuka-Alcalá, A., Huang, L., Theodosakis, N., & Bosenberg, M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25019 · Cited by 43
Dabrafenib Therapy for Advanced Melanoma
Trinh, V. A., Davis, J. E., Anderson, J. E., & Kim, K. B. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013513009 · Cited by 40
Self-citationMaverakis, E., Tran, K. A., Cheng, M., Mitra, A., Ogawa, H., Shi, V. Y., Olney, L. P., & Kloxin, A. M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s93545 · Cited by 42
Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas
Zhang, J., Yao, T.-W., Hashizume, R., Hariono, S., Barkovich, K. J., Fan, Q., Prados, M. D., James, C. D., Weiss, W. A., & Nicolaides, T. P. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2333-4 · Cited by 40
Chowdhary, M., Patel, K. R., Danish, H. H., Lawson, D. H., & Khan, M. K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s119428 · Cited by 40
BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
Migliorini, D., Aguiar, D., Vargas, M. I., Lobrinus, A. J., & Dietrich, P. (2017) · Neurology · doi:10.1212/wnl.0000000000003767 · Cited by 40
Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy
Li, Y.-Y., Feun, L. G., Thongkum, A., Tu, C.-H., Chen, S.-M., Wangpaichitr, M., Wu, C., Kuo, M. T., & Savaraj, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061297 · Cited by 40
Precision treatment for cancer: Role of prognostic and predictive markers
Duffy, M. J., & Crown, J. P. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.865700 · Cited by 41
Future Translational Applications From the Contemporary Genomics Era
Fox, C. S., Hall, J. L., Arnett, D. K., Ashley, E. A., Delles, C., Engler, M. B., Freeman, M. W., Johnson, J. A., Lanfear, D. E., Liggett, S. B., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000211 · Cited by 39
The next steps in next-gen sequencing of cancer genomes
Hayes, D. N., & Kim, W. Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci68339 · Cited by 40
Principles of Melanoma Staging
Boland, G. M., & Gershenwald, J. E. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_5 · Cited by 40
Ipilimumab for advanced melanoma
Berrocal, A., Arance, A. M., Lopez-Martin, J. A., Soriano, V., Muñoz‐Couselo, E., Alonso, L., Espinosa, E., Criado, P. L., Valdivia, J., & Martín‐Algarra, S. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000108 · Cited by 39
Malignant melanoma—The cradle of anti-neoplastic immunotherapy
Koller, K. M., Wang, W., Schell, T. D., Cozza, E. M., Kokolus, K. M., Neves, R. I., Mackley, H. B., Pameijer, C. R., Leung, A. M., Anderson, B. E., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.010 · Cited by 40
Research progress in advanced melanoma
Luo, C., & Shen, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.037 · Cited by 41
Wongchenko, M. J., McArthur, G. A., Dréno, B., Larkin, J., Ascierto, P. A., Sosman, J. A., Andries, L. J., Kockx, M. M., Hurst, S. D., Caro, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0172 · Cited by 39
Self-citation
Metadata
- Authors
- Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K. D., Amaravadi, R. K., Chmielowski, B., Lawrence, H. J., Shyr, Y., Ye, F., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K., & Ribas, A.
- Affiliations
- Vanderbilt University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Abramson Cancer Center (US)
- University of Colorado Denver (US)
- New York University (US)
- Moffitt Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- University of Newcastle Australia (AU)
- Melanoma Institute Australia (AU)
- Vanderbilt-Ingram Cancer Center (US)
- University of California, Los Angeles (US)
- Vanderbilt University Medical Center (US)
- Plexxikon (United States) (US)
- ORCID
- Sosman, Jeffrey A.
- Kim, Kevin B.
- Schuchter, Lynn
- Gonzalez, Rene
- Pavlick, Anna C.
- Weber, Jeffrey S.
- McArthur, Grant A.
- Hutson, Thomas E.
- Moschos, Stergios J.
- Flaherty, Keith T.
- Hersey, Peter
- Kefford, Richard
- Lawrence, Donald
- Puzanov, Igor
- Lewis, Karl D.
- Amaravadi, Ravi K.
- Chmielowski, Bartosz
- Shyr, Yu
- Ye, Fei
- Li, Jiang
- Lee, Richard J.
- Ribas, Antoni
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-23
- Volume
- 366
- Issue
- 8
- Pages
- 707-714
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3724515
- OpenAlex
- W2168143310
- Cited by
- 2,156
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 56 · 2023: 85 · 2022: 113 · 2021: 88 · 2020: 110 · 2019: 109 · 2018: 132 · 2017: 171 · 2016: 198 · 2015: 258 · 2014: 318 · 2013: 306 · 2012: 160
- FWCI
- 133.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (K24CA097588, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, metastatic melanoma, BRAF inhibitors, overall survival, overall response rate, duration of response, progression-free survival, cutaneous squamous cell carcinoma, keratoacanthoma, adverse events
- MeSH terms
- Vemurafenib, Adult, Aged, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Sulfonamides, Treatment Outcome, Disease Progression, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
